340B Advocacy Alliance Bulletin
The AHA today told the CMS that a proposal included in the agency’s calendar year 2027 physician fee schedule proposed rule to make reporting mandatory as of Jan. 1, 2027, significantly understates the time, resources and complexity required for hospitals to comply.
The Health Resources and Services Administration’s Office of Pharmacy Affairs Sept. 8 released information on the 340B Office of Pharmacy Affairs Information System Paperwork Reduction Act forms.
The AHA Aug. 26 urged the Centers for Medicare & Medicaid Services not to finalize two proposals in the calendar year 2027 outpatient prospective payment system proposed rule,
The AHA today submitted comments to Sen. Bill Cassidy, R-La., on the 340B Drug Pricing Integrity and Affordability for Patients Act (340B for Patients Act).
Reminder: Submit comments on calendar year 2027 outpatient prospective payment system proposed rule by Aug. 31.
The AHA Aug. 12 at 3 p.m. ET will host a call for 340B hospitals to discuss several aspects of the 340B Drug Pricing Program, including the rebate model and congressional activities.
The AHA today issued a Legislative Advisory that includes a detailed summary of the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act or SUSTAIN 340B Act.
The AHA today issued a Regulatory Advisory that includes a detailed summary of the Health Resources and Services Administration announcement on the new 340B Rebate Model Program
A bipartisan group of senators today introduced the Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act),
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers to use rebates rather than upfront discounts to effectuate the 340B ceiling price for certain drugs purchased by 340B covered entities.